Stacey R. Lewis

Ursodiol Prophylaxis against Hepatic Complications of Allogeneic Bone Marrow Transplantation

N. Callander, J. Essell, M. Snyder, 1998, Annals of Internal Medicine.

In vitro activity of telavancin and occurrence of vancomycin heteroresistance in isolates from patients enrolled in phase 3 clinical trials of hospital-acquired pneumonia.

K. Krause, S. Barriere, C. S. Lunde, 2012, Diagnostic microbiology and infectious disease.

Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.

K. Krause, S. Hegde, J. Blais, 2010, The Journal of antimicrobial chemotherapy.

Specificity of Induction of the vanA and vanB Operons in Vancomycin-Resistant Enterococci by Telavancin

M. Mammen, J. Janc, K. Krause, 2010, Antimicrobial Agents and Chemotherapy.

Antistaphylococcal Activity of TD-1792, a Multivalent Glycopeptide-Cephalosporin Antibiotic

K. Krause, J. Blais, Bret M. Benton, 2011, Antimicrobial Agents and Chemotherapy.